Lucid Diligence Brief - BioPharma

AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief

AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Anthropic acquires Coefficient Bio

Lucid Diligence Brief: Anthropic acquires Coefficient Bio Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion

Lucid Diligence Brief: Novo Nordisk to acquire Akero Therapeutics for up to…


Privacy Preference Center